Beractant
JFDA label: Survanta Vial 8ml
Mechanism of Action
— Surfactant agent
Indications
Approved
- Respiratory distress syndrome
Contraindications
Source: Lexicomp
- There are no contraindications listed in the manufacturer's labeling Absolute
Adverse Reactions
Other (2)
Very Common Cardiovascular: Bradycardia (transient)
Common Respiratory: Oxygen desaturation
Dosing
Source: Lexicomp
Warnings & Precautions
Source: Lexicomp
Mucous plugs
Marked impairment of ventilation during or shortly after dosing may indicate mucous plugging of the endotracheal tube; suctioning all neonates prior to administration may decrease chance of endotracheal tube obstruction. Replace endotracheal tube immediately if obstruction is not removed with suctioning.
Nosocomial sepsis
There is an increased risk of post-treatment nosocomial sepsis in treated neonates this increased risk was not associated with increased mortality.
Transient adverse effects
Transient episodes of bradycardia and decreased oxygen saturation may occur. Discontinue dosing procedure and initiate measures to alleviate the condition; may reinstitute after the patient is stable. Rales and moist breath sounds may occur; endotracheal suctioning or other remedial action is necessary if clear-cut signs of airway obstruction are present. Other warnings/precautions:
Administration
Intended for endotracheal administration only.
Appropriate use
Use in neonates 1,750 grams birth weight has not been evaluated.
Lung oxygenation/lung compliance
Produces rapid improvements in lung oxygenation and compliance that may require frequent adjustments to oxygen delivery and ventilator settings; hyperoxia may occur within minutes of administration.
Trained personnel
Rapidly affects oxygenation and lung compliance; restrict use to a highly-supervised clinical setting with immediate availability of clinicians experienced in intubation and ventilatory management of premature neonates.
Pregnancy & Lactation
Pregnancy
Beractant is only indicated for use in premature neonates
Lactation
Beractant is only indicated for use in premature neonates
Monitoring
| Clinical pearl | Continuous ECG and arterial or transcutaneous measurement of systemic oxygen and carbon dioxide during administration; arterial blood gases |
|---|
Biology & Pharmacokinetics
Pharmacokinetics
Registered Products (4)
| Brand | Form / strength | Pack | Agent | Citizen (JOD) |
|---|---|---|---|---|
| BLES | Vial 27 mg/1 ml, 176-500 mcg/ml | 5 ml pack varies | ALTHAER DRUG STORE | — |
| BLES | Vial 27 mg/1 ml, 176-500 mcg/ml | 3 ml pack varies | ALTHAER DRUG STORE | — |
| Survanta | Vial 25 mg/ml | 1 vial pack varies | Sukhtian Group | — |
| Survanta Vial | Vial 25 mg/ml | 1 vial pack varies | Hussam Al Nmer Drug Store | — |